These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12544490)

  • 41. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.
    Arruda VR; Fields PA; Milner R; Wainwright L; De Miguel MP; Donovan PJ; Herzog RW; Nichols TC; Biegel JA; Razavi M; Dake M; Huff D; Flake AW; Couto L; Kay MA; High KA
    Mol Ther; 2001 Dec; 4(6):586-92. PubMed ID: 11735343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
    Wiwanitkit V
    Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene Therapy for Hemophilia.
    Nathwani AC; Davidoff AM; Tuddenham EGD
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):853-868. PubMed ID: 28895852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene therapy for hemophilia.
    Nathwani AC
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):1-8. PubMed ID: 31808868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene therapy strategies for hemophilia: benefits versus risks.
    Petrus I; Chuah M; VandenDriessche T
    J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gene therapy for hemophilia.
    Ponder KP
    Curr Opin Hematol; 2006 Sep; 13(5):301-7. PubMed ID: 16888433
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
    Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
    J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
    Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
    Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.
    Mingozzi F; Schüttrumpf J; Arruda VR; Liu Y; Liu YL; High KA; Xiao W; Herzog RW
    J Virol; 2002 Oct; 76(20):10497-502. PubMed ID: 12239326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
    Lu H; Chen L; Wang J; Huack B; Sarkar R; Zhou S; Xu R; Ding Q; Wang X; Wang H; Xiao W
    Hum Gene Ther; 2008 Jun; 19(6):648-54. PubMed ID: 18500941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical gene transfer studies for hemophilia B.
    High KA
    Semin Thromb Hemost; 2004 Apr; 30(2):257-67. PubMed ID: 15118937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter.
    Hagstrom JN; Couto LB; Scallan C; Burton M; McCleland ML; Fields PA; Arruda VR; Herzog RW; High KA
    Blood; 2000 Apr; 95(8):2536-42. PubMed ID: 10753832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current and future prospects for hemophilia gene therapy.
    Ward P; Walsh CE
    Expert Rev Hematol; 2016 Jul; 9(7):649-59. PubMed ID: 27153210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Portal vein delivery of viral vectors for gene therapy for hemophilia.
    Sherman A; Schlachterman A; Cooper M; Merricks EP; Raymer RA; Bellinger DA; Herzog RW; Nichols TC
    Methods Mol Biol; 2014; 1114():413-26. PubMed ID: 24557919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adeno-associated viral vectors for the treatment of hemophilia.
    High KA; Anguela XM
    Hum Mol Genet; 2016 Apr; 25(R1):R36-41. PubMed ID: 26614390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.